April 2025 Tender Notification
In April 2025, Pharmac has not resolved to award any tenders for Principal Supply Status for products included in the 2024/25 Invitation to Tender dated 31 October 2024.
We are currently working to improve our decision making through further consultation for tender decisions. As part of this, there have been some changes to our usual timeframes. We are still working through evaluation of items included in the 2023/24 and 2024/25 Invitation to Tender and expect to announce these decisions over the coming months. We appreciate your patience and understanding while we improve our processes.
- 28 April 2025 Tender Notification [PDF 110 KB]
Tender declines – Products where no tender is to be awarded for Principal Supply Status
Pharmac has resolved not to award tenders for Principal Supply Status for the following products listed in the 2022/23 Invitation to Tender, dated 31 October 2022.
|
Chemical Name |
Line Item |
|---|---|
|
Moxifloxacin |
Tab 400 mg |
Pharmac has resolved not to award tenders for Principal Supply Status for the following products listed in the 2023/24 Invitation to Tender, dated 31 October 2023.
|
Chemical Name |
Line Item |
|---|---|
|
Ertapenem |
Inj 1 g |
|
Netupitant with palonosetron |
Cap netupitant 300 mg with palonosetron 500 mcg |
Pharmac has resolved not to award tenders for Principal Supply Status for the following products listed in the 2024/25 Invitation to Tender, dated 31 October 2024.
|
Chemical Name |
Line Item |
|---|---|
|
Fingolimod |
Cap 0.5 mg |
|
Multivitamins |
Tab (BPC cap strength) |
|
Nortriptyline hydrochloride |
Tab 10 mg |
|
Nortriptyline hydrochloride |
Tab 25 mg |
|
Omeprazole |
Inj 40 mg ampoule with diluent |
|
Omeprazole |
Inj 40 mg |
|
Pancreatic enzyme |
Cap 150 mg |
|
Pancreatic enzyme |
Cap 175 mg |
|
Pancreatic enzyme |
Cap 300 mg |
|
Pancreatic enzyme |
Cap 420 mg |
|
Progesterone |
Cap 100 mg |
|
Progesterone |
Cap 200 mg |
|
Methylphenidate hydrochloride (widened access) |
Cap modified release 60 mg |
|
Methylphenidate hydrochloride (current access) |
Cap modified release 60 mg |
For products included in the 2023/24 and 2024/25 Invitation to Tender where no announcement has yet been made, a decision is still pending subject to Pharmac Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made.
If you have any queries regarding this notification, please contact Pharmac on 0800 66 00 50.